Literature DB >> 22806149

[Autoimmune liver diseases].

N Pannicke1, C Schramm, A W Lohse.   

Abstract

Autoimmune liver diseases are divided into autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). They play an important role in the differential diagnosis of acute and chronic liver diseases. Diagnostic criteria consist of biochemical parameters (liver function tests, immunoglobulins, autoantibodies), imaging (ultrasound, MRCP, ERCP) and histopathologic characteristics. The treatment of choice in AIH is a combined immunosuppressive therapy of prednisolone and azathioprine. Ursodeoxycholic acid is the treatment of choice for PBC and improves liver biochemistry and prolongs transplant-free survival by slowing histological progression in the majority of patients. To date, there is no effective medical treatment option for patients with PSC.

Entities:  

Mesh:

Year:  2012        PMID: 22806149     DOI: 10.1007/s00108-012-3096-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

1.  Diagnosis and management of autoimmune hepatitis.

Authors:  Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

2.  EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

Authors: 
Journal:  J Hepatol       Date:  2009-06-06       Impact factor: 25.083

Review 3.  Primary biliary cirrhosis: a 2010 update.

Authors:  Raoul Poupon
Journal:  J Hepatol       Date:  2010-02-18       Impact factor: 25.083

4.  Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.

Authors:  Christophe Corpechot; Olivier Chazouillères; Raoul Poupon
Journal:  J Hepatol       Date:  2011-04-13       Impact factor: 25.083

5.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

6.  Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry.

Authors:  Christoph Schramm; Michael Bubenheim; René Adam; Vincent Karam; John Buckels; John G O'Grady; Neville Jamieson; Stephen Pollard; Peter Neuhaus; Michael M Manns; Robert Porte; Denis Castaing; Andreas Paul; Oscar Traynor; James Garden; Styrbjörn Friman; Bo-Goran Ericzon; Lutz Fischer; Stefan Vitko; Marek Krawczyk; Herold J Metselaar; Aksel Foss; Murat Kilic; Keith Rolles; Patrizia Burra; Xavier Rogiers; Ansgar W Lohse
Journal:  Liver Transpl       Date:  2010-04       Impact factor: 5.799

Review 7.  Autoimmune hepatitis.

Authors:  Ansgar W Lohse; Giorgina Mieli-Vergani
Journal:  J Hepatol       Date:  2010-12-15       Impact factor: 25.083

8.  Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.

Authors:  Michael P Manns; Marek Woynarowski; Wolfgang Kreisel; Yoav Lurie; Christian Rust; Elimelech Zuckerman; Matthias J Bahr; Rainer Günther; Rolf W Hultcrantz; Ulrich Spengler; Ansgar W Lohse; Ferenc Szalay; Martti Färkkilä; Markus Pröls; Christian P Strassburg
Journal:  Gastroenterology       Date:  2010-06-22       Impact factor: 22.682

Review 9.  Evolving concepts in primary sclerosing cholangitis.

Authors:  Elisabeth Krones; Ivo Graziadei; Michael Trauner; Peter Fickert
Journal:  Liver Int       Date:  2011-08-17       Impact factor: 5.828

10.  The natural history of small-duct primary sclerosing cholangitis.

Authors:  Einar Björnsson; Rolf Olsson; Annika Bergquist; Stefan Lindgren; Barbara Braden; Roger W Chapman; Kirsten M Boberg; Paul Angulo
Journal:  Gastroenterology       Date:  2008-01-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.